LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Fermé

3.72 1.09

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.69

Max

3.89

Chiffres clés

By Trading Economics

Revenu

44M

-26M

Ventes

-5.8M

42M

Marge bénéficiaire

-61.388

Employés

550

EBITDA

44M

-22M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+10.8% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

246M

1.3B

Ouverture précédente

2.63

Clôture précédente

3.72

Score Technique

By Trading Central

Confiance

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

10 déc. 2025, 22:02 UTC

Résultats

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 déc. 2025, 21:46 UTC

Résultats

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 déc. 2025, 23:52 UTC

Acquisitions, Fusions, Rachats

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 déc. 2025, 23:43 UTC

Market Talk

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 déc. 2025, 23:36 UTC

Market Talk

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 déc. 2025, 23:20 UTC

Résultats

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 déc. 2025, 23:15 UTC

Résultats

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 déc. 2025, 22:59 UTC

Market Talk
Résultats
Acquisitions, Fusions, Rachats

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 déc. 2025, 22:45 UTC

Market Talk

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 déc. 2025, 22:40 UTC

Résultats

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 déc. 2025, 22:06 UTC

Acquisitions, Fusions, Rachats

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 déc. 2025, 22:06 UTC

Résultats

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 déc. 2025, 22:02 UTC

Résultats

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 déc. 2025, 22:00 UTC

Résultats

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 déc. 2025, 21:53 UTC

Résultats

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 déc. 2025, 21:50 UTC

Acquisitions, Fusions, Rachats

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 déc. 2025, 21:50 UTC

Market Talk
Résultats
Acquisitions, Fusions, Rachats

Financial Services Roundup: Market Talk

10 déc. 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 déc. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

10 déc. 2025, 21:45 UTC

Acquisitions, Fusions, Rachats

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 déc. 2025, 21:33 UTC

Résultats

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 déc. 2025, 21:32 UTC

Résultats

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 déc. 2025, 21:28 UTC

Acquisitions, Fusions, Rachats

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 déc. 2025, 21:25 UTC

Résultats

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 déc. 2025, 21:18 UTC

Acquisitions, Fusions, Rachats

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 déc. 2025, 21:16 UTC

Résultats

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 déc. 2025, 21:15 UTC

Acquisitions, Fusions, Rachats

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 déc. 2025, 21:15 UTC

Résultats

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 déc. 2025, 21:14 UTC

Résultats

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 déc. 2025, 21:14 UTC

Résultats

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

10.8% hausse

Prévisions sur 12 Mois

Moyen 4 USD  10.8%

Haut 4 USD

Bas 4 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

2

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

2.02 / 2.115Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat